UH scientists may have solved kava mystery

honadv
By Kevin Dayton
Advertiser Big Island Bureau
HILO, Hawai’i — A team of University of Hawai’i scientists may have solved the mystery of why some Europeans who used products containing kava extract suffered severe liver damage, prompting a number of nations to ban sales of the herbal supplement.

The culprit may be a compound found in the stem peelings and leaves of the kava plant — known in Hawai’i as ‘awa — but not in the roots that are used to make the traditional kava drink consumed by Pacific Islanders.

Just to be safe, people should avoid tea or anything else made from the leaves or stems of the plant, according to C.S. Tang, professor of molecular biosciences and biosystems engineering at UH-Manoa.

Bans in Singapore, Germany, Canada, the United Kingdom and elsewhere wiped out pharmaceutical sales of kava and virtually destroyed it as an export crop in Hawai’i. While kava supplements are not banned in the United States, the Food and Drug Administration issued an advisory in March 2002 warning of the potential risk of severe liver injury from dietary supplements containing kava.

The health alarms left farmers in Hamakua and elsewhere with crops that were hardly worth harvesting.

READ COMPLETE STORY

Analysis of Kava Side Effects Reports Concerning the Liver

Translation to English by Lindenmaier M and Brinckmann J
31. December 2001

Analysis of hepatotoxic reactions listed by the BfArM (German Federal Institute for Drugs and Medical Devices)

The BfArM has recently informed industry and media about reported side effects that may be associated with the ingestion of kava preparations (2;3). In this preliminary information, it is stated that the Institute proposes to revoke marketing authorization for kava -containing drugs including homeopathic preparations with a final concentration of D6. Henceforth, the manufacturers have been given the opportunity, within 4 weeks time of receipt of the letter, to respond with its position concerning the proposed measures.Even though the announcements are rather serious, the need for urgency comes as a surprise: with regard to the drug safety protocol developed in Switzerland in 2000, of which the German health authorities also had knowledge of, the information status has not fundamentally changed. Yet on October 19, 2000, theGerman health authorities stated in a 10 part report that the BfArM had no intentions of conducting a new risk evaluation for kava products in Germany (1). ???

The announcement of a drug safety protocol through the BfArM was based on a listing of 24 cases of side effects in connection with serious hepatotoxic effects ranging up to liver failure, (cholestatic) hepatitis or cirrhosis of the liver. In 18 of these cases, the BfArM classified an association with kava as probable or possible. In one case, the adverse effect on the liver was fatal. Five cases were without any concomitant medication. Two reports couldnot be evaluated due a lack of clinical data. Also, in the cases involvingco-medication, the BfArM considered kava to be responsible for the side effect. Serological investigations, as far as they were carried out, were negative in all cases.

Closer inspection of the presented cases provides, however, another outcome andraises considerable questions with regard to the BfArM accuracy or carefulness in association with sensible procedures. For example, the report regarding virus serology is misleading: such investigations were conducted in only the fewest of cases, and these were primarily the ones reported in Switzerland. The adverse event case reports from Switzerland are collectively characterized as being representative, while the evaluation of the listings bythe BfArM is far from compliance with the current standards required to fulfill relevant European guidelines.

When one examines the reactions in detail, it appears that the BfArM’s classification of causality linked to kava, is, to a large extent, incomprehensible, and arbitrary. Moreover, in its evaluation of cases, the BfArM had not taken into consideration various existing pieces of information, for example those with regard to other possible causes. One extreme example may be concerning the aforementioned lethal case: in this instance, it was known to the Institute that the cause of liver failure was several years of alcoholabuse, and that kava was not involved in the genesis of the liver symptoms. The autopsy had shown that the cirrhotic process had already started long before the adminstration of kava began!

The second, internal listing documented that this circumstance was known to the BfArM, but this listing has not been made accessible to the manufacturers for use in rebuttal statements regarding the notice of possible marketing revocation. This second listing contained a compilation of all known suspected cases (32 in all), including those reported in Switzerland and those published in the literature. This listing is indeed carefully conveyed as being an ?official? paper, however it still contains a range of obvious errors.

Because the ?non-official? second listing of the BfArM is complete in regard to the sources referred to in this evaluation, the 24 reports of side effects initially reported by BfArM are consequently not being used as the basis of discussion, but rather the 32 cases that were entered into the second listing. In addition to the BfArM’s two listings, other sources of information for the present case evaluation include the

Interkantonalen Kontrollstelle (IKS) der Schweiz (Swiss Intercantonal Agency for Control of Medicines), the pharmacovigilance databank of the WHO, as well as concerned product manufacturers.The listing of cases that are suspected to be kava-related by the Arzneimittelkomission der deutschen ?rzteschaft (AKD?) (Drug Commission of the German Physician’s Association) is not included. The AKD?’s listing of the most recent adverse event reports contains no indications of liver toxicity from kava products. Moreover, theAKD? does not release the product names publicly, which prevents a meaningful use of the data a priori.?

Read Entire Article Here

Analysis of Kava Side Effects Reports Concerning the Liver–Literature

Translation to English by Lindenmaier M and Brinckmann J
31. December 2001

Analysis of hepatotoxic reactions listed by the BfArM (German Federal Institute for Drugs and Medical Devices)

[1] Anonym. Konsequenzen f?r Kava-Pr?parate in der Schweiz. Pharm Ztg 2000; 145(42):3494.

[2] Arzneimittelkommission der Deutschen Apotheker. Kava-Kava und Kavain-haltige Arzneimittel. Pharm Ztg 2001; 146(46):4017.

[3] Arzneimittelkommission der Deutschen Apotheker. Kava-Pr?parate und Kavain-haltige Arzneimittel. Dtsch Apoth Ztg 2001; 141(46):5412.

[4] Barrio J, Castiella A, Cosme A, Lopez P, Fernandez J, Arenas JI. [Hepatotoxicity caused by cloxacillin]. Rev Esp Enferm Dig 1997; 89(7):559-560.

[5] Barrio J, Castiella A, Lobo C, Indart A, Lopez P, Garcia-Bengoechea M et al. [Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis]. Rev Esp Enferm Dig 1998; 90(7):523-526.

[6] Bauer TM, Bircher AJ. Drug-induced hepatocellular liver injury due to benzylpenicillin with evidence of lymphocyte sensitization. J Hepatol 1997; 26(2):429-432.

[7] Beeley L, Gourevitch A, Kendall MJ. Jaundice after oral penicillin. Lancet 1976; 2(7998):1297.

[8] Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11(2):272-276.

[9] Bint AJ. Esters of penicillins–are they hepatotoxic? J Antimicrob Chemother 1980; 6(6):697-699.

[10] Bralet MP, Zafrani ES. [Hepatitis caused by the amoxicillin-clavulanic acid combination. An example of drug-induced biliary hepatotoxicity]. Ann Pathol 1996; 16(6):425-429.

[11] Brauer R-B, Pfab R, Becker K, Berger H, Stangl M. Fulminantes Leberversagen nach Einnahme des pflazlichen Heilmittels Kava-Kava. Z Gastroenterol 2001; 39:491.

[12] Bustamante BM, Perez AF, Rayon MM, Garcia HA, Berenguer LJ. [Cholestatic hepatitis caused by amoxycillin-clavulanic acid. Report of a new case]. Gastroenterol Hepatol 1997; 20(4):187-189.

[13] Caballero Plasencia AM, Valenzuela BM, Martin Ruiz JL, Guilarte Lopez-Manas J. [Hepatotoxicity caused by amoxicillin, clavulanic acid or both?]. Gastroenterol Hepatol 1997; 20(1):45-46.

[14] Escher M, Desmeules J. Hepatitis associated with Kava, a herbal remedy for anxiety. Br Med J 2001; 322(20.01.01):139.

[15] Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol 1997; 12(9-10):S242-S250.

[16] Galindo C, Buenestado J, Rene JM, Pinol MC. [Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid]. Rev Esp Enferm Dig 1995; 87(8):597-600.

[17] George DK, Crawford DH. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996; 15(1):79-85.

[18] Goland S, Malnick SD, Gratz R, Feldberg E, Geltner D, Sthoeger ZM. Severe cholestatic hepatitis following cloxacillin treatment. Postgrad Med J 1998; 74(867):59-60.

[19] Goldstein LI, Ishak KG. Hepatic injury associated with penicillin therapy. Arch Pathol 1974; 98(2):114-117.

[20] Hautekeete ML. Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995; 58(3-4):290-296.

[21] Hewitt J, Hammond L. Adverse hepatic events associated with drug therapy. Med J Aust 1996; 165(6):347, 350.

[22] Kraft M, Spahn TW, Menzel J, Senninger N, Dietl K-H, Herbst H et al. Fulminantes Leberversagen nach Einahme des pflanzlichen Antidepressivums Kava-Kava. Dtsch med Wschr 2001; 126(36):970-972.

[23] Kurowski V. [Cholestatic jaundice induced by amoxicillin and clavulanic acid]. Dtsch Med Wochenschr 1996; 121(12):390-391.

[24] Larrey D, Palazzo L, Benhamou JP. Terfenadine and hepatitis. Ann Intern Med 1985; 103(4):634.

[25] Mizoguchi Y, Iwasaki M, Tsutsui H, Kobayashi K, Monna T, Morisawa S. Preparation of a drug-induced allergic hepatic disorder model with penicillin as hapten. Osaka City Med J 1991; 37(2):133-140.

[26] Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr 1976; 89(5):835-838.

[27] Onate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, Gonzalez dZ, Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995; 20(2):474-475.

[28] Paine TF, Jr. Updating the side effects of the penicillins. Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi 1978; 11(3):104-109.

[29] Perman E. [A severe adverse effect of penicillin on the liver. Drug insurance covered the compensation]. Lakartidningen 1998; 95(34):3536.

[30] Russmann S, Escher M, Stoller R, Lauterburg BH. Hepatotoxicity of Kava Kava (Piper methysticum) containing herbal drugs. Recent cases in Switzerland and investigations regarding the mechanism. J Exp Klin Pharmakol Toxicol 2001; 363(4):S40.

[31] Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Int Med 2001; 135(1):68-69.

[32] Sahai A, Villeneuve JP. Terfenadine-induced cholestatic hepatitis. Lancet 1996; 348(9026):552-553.

[33] Sa? M, Schnabel S, Kr?ger J, Liebe S, Schareck WD. Akutes Leberversagen durch Kava-Kava – eine seltene Indikation zur Lebertransplantation. Z Gastroenterol 2001; 39:491.

[34] Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 1992; 37(1):150-152.

[35] Stoller R. Lebersch?digungen unter Kava-Extrakten. Schweiz ?rzteztg 2000; 81(24):1335-1336.

[36] Strahl S, Ehret V, Dahm HH, Maier KP. Nekrotisierende Hepatitis nach Einnahme pflanzlicher Heilmittel. Dtsch med Wschr 1998; 123:1410-1414.

[37] Weber E. Taschenbuch der unerw?nschten Arzneimittelwirkungen. 2 ed. Stuttgart, New York: Gustav Fischer Verlag, 1988.

[38] Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994; 33(3):387-401.

[39] Yusoff IF, Nairn P, Morgan CA. Multiple organ failure related to pantoprazole. Aust N Z J Med 1999; 29(6):833-834.

Read Complete Article Here